PT Prodia Widyahusada Tbk · IDX:PRDA
PT Prodia Widyahusada Tbk — 9M2024 Earnings Presentation
27 slides from PT Prodia Widyahusada Tbk's earnings presentation, 2024
Slide 1: 9M2024 Results Update
9M2024 Results Update PT Prodia Widyahusada Tbk | P R D A . J K Prodia.co.id
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Corporate Overview
CORPORATE OVERVIEW Prodia.co.id
Slide 4: 9M2024 Performance Highlight
9M2024 Performance Highlight 50+ More than 50 years experience in Clinical Lab Industry since 1973 IDR 1,598 Billion 9M2024 Revenue (-0.9% YoY), CAGR 5yrs (+5.2%) Has the most recognized Brand in Indonesia >1.9 Million Largest private independent clinical lab 9M2024 Visit (-3.4% YoY), CAGR 5yrs (+1.
Slide 5: Extensive Milestone to Grow
Extensive Milestone to Grow 2017 • Received Westgard Six 2011 Sigma Certification & KALK Accreditation Next-Gen Lab: 2008 • Established Prodia • Develop Prodia Mobile • 18 new test launched in preventive, Next-Gen Lab: • Establishment of Prodia ChildLab 1990 predictive, screening, diagnostic, • 29 n
Slide 6: Experienced Management Team
Experienced Management Team With more than 20 years experience in delivering growth and innovation of Prodia Years of 51 Years of 51 Experience 40 Years of 49 Years of 32 Years of Experience Experience Experience Experience Gunawan Endang Joseph Fellipus Keri Lestari Andi Wijaya Prawiro Soeharto Pet
Slide 7: Shareholders Composition
Shareholders Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 15% 28% Distributor for Contract Research Research, therapy and medical equipment Organization banking of stem cell 39% PT Prodia Widyahusada Tbk In Vitro Diagnostics Nationwide Outlet Network across Indonesia Occupational Dis
Slide 8: Investment Highlight
INVESTMENT HIGHLIGHT Prodia.co.id
Slide 9: Largest Independent Labs Chain
Largest Independent Labs Chain Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2021-2023) (Billion IDR) 5YRS CAGR 5YRS CAGR 37.9% 40.5% 40.1% 6.5% 5.8% 33.1% 28.0% 28.1% 7,225 2,737 2021 2022 2023 2,209 2,246 5,455 5,608 1,782 1,926 4,222 4,552 4,874 1,638 29.0% 3
Slide 10: Strong Operational Track Record
Strong Operational Track Record Visits Revenue (in million) (in IDR Trillion) 2.8 2.22 CAGR CAGR 6.8% 2.7% 2.4 1.60 Prodia has generated continuous revenue growth and increasing 2018 2019 2020 2021 2022 2023 2018 2019 2020 2021 2022 2023 number of visits that Revenue per Visit EBITDA supported Compa
Slide 11: Comprehensive Service Offering
Comprehensive Service Offering With multiple customer segments Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation One-stop shop, General Medical offering the most Genomic Testing Preventive Treatment Check-Up Services comprehensive ran
Slide 12: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved “Hub and spoke” model offers Centralized information scalable platform reducing Prodia Clinical Labs, Hospitals with integrated IT and Other Clinics may refer Prodia Re
Slide 13: Maintain Strong and Long-Term Relationship with Medical Community
Maintain Strong and Long-Term Relationship with Medical Community Strong relationships through the work Introduced new tests, such as NIPT ProSafe, Amino of more than 500 Marketing and Acid Profile, CArisk, DIArisk, New Born Screening, Laboratory Information Service Autoimmune Liver Disease Profile,
Slide 14: Pioneer in New Lab Testing; Digital Healthcare Platform
Pioneer in New Lab Testing Offer more than 3,000 type of testing, with referral Target to launch minimum 10 new Partnership to NUH Singapore and Quest Diagnostic US testing every year One of The Largest Digital Healthcare Platform One Stop Health Solution App Digital Diagnostic Partner U by Prodia P
Slide 15: Market Overview & Growth Strategy
MARKET OVERVIEW & GROWTH STRATEGY Prodia.co.id
Slide 16: 2024 Indonesia Economic Outlook
2024 Indonesia Economic Outlook Fast forward sustainable and inclusive economic transformation 4.8 - 5.7% Indonesia’s GDP Growth Projection for 2024 Global economic uncertainty expected to GDP Growth Projection 2024 continue in 2024 and Indonesia World lead an impact on consumption and Indonesia’s G
Slide 17: Company's Growth Strategy
Company's Growth Strategy Expand our presence and grow our Orchestrate highest quality health ecosystem network of outlets in both physical and and leading digital health ecosystem in digital channel in Indonesia Indonesia Upgrade existing clinical laboratories to Reinforce Company's subsidiary: Pro
Slide 18: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Predictive & Separation Science Diagnostic Laboratory Laboratory Next Generation Laboratory Anatomical Pathology Cancer Molecular Laboratory Diagnostic Advance Immunology Advance Microbiology
Slide 19: Business Update
BUSINESS UPDATE Prodia.co.id
Slide 20: Outlet Development
Outlet Development 2016-2024 Outlet Development 2024 Outlet Development Target 259 283 292 287 267 259 276 295 341 5+ 2 5 7 4** 4** 4** 4** 4** 4** Hospital Labs 9 11 14 14 12 9 11 10 13 Management* *includes hospital lab Total 3 new Genomic Sites open in 9M2024 108 98 113 and genomic site 118 130 1
Slide 21: Customer Centric Model
Customer Centric Model To deliver solution for customer needs • Routine, Esoteric, Genomic Tests • Wellness Package Professional Contact Centre • Prodia for Doctor • Disease Screening • Call Centre 1500-830 • U by Prodia Package • Chat WhatsApp 0855-1500-830 • ProdiaLink for External Referrals • Cha
Slide 22: Financial Update
FINANCIAL UPDATE Prodia.co.id
Slide 23: 9M2024 Revenue (Unaudited)
9M2024 Revenue (Unaudited) Revenue (Unaudited) Quarterly Revenue (Unaudited) In IDR Billion In IDR Billion 2018 2019 2020 2021 FY18-FY23 CAGR +6.8% 9M19-9M24 CAGR +5.2% • Revenue improved in 2022 2023 2024 3Q24 vs 2Q24 mostly driven by B2B customer segment 2,652 due to 2H seasonality 9M23-9M24 Growt
Slide 24: 9M2024 Gross Profit & Net Income
9M2024 Gross Profit & Net Income Gross Profit Net Income in IDR Billion In IDR Billion FY18-FY23 CAGR +6.9% 9M19-9M24 CAGR +5.9% FY18-FY23 CAGR +8.1% 9M19-9M24 CAGR +9.9% Gross Profit Margin Net Income Margin 9M23-9M24 9M23-9M24 Growth: -1.9% Growth: -17.6% 1,633 25.7% 623.2 1,327 1,319 60.9% 60.7%
Slide 25: 9M2024 COGS & OPEX
9M2024 COGS & OPEX COGS OPEX in IDR Billion In IDR Billion FY18-FY23 CAGR +6.6% 9M19-9M24 CAGR +4.3% FY18-FY23 CAGR +5.8% 9M19-9M24 CAGR +4.0% COGS to revenue Opex to revenue Direct Cost 9M23-9M24 G&A Expense 9M23-9M24 Indirect Cost Growth: +0.7% Marketing Expense Growth: +5.4% 146 74 125 157 200 42
Slide 26: 9M2024 Financial Summary
9M2024 Financial Summary (in IDR Bn) 9M2024 9M2023 Change (in IDR Bn) 9M2024 9M2023 Change Revenue 1,598.4 1,612.4 -0.9% Total Asset 2,744.0 2,691.5 +2.0% Gross Profit 960.0 978.4 -1.9% Total Equity 2,406.0 2,344.8 +2.6% EBIT 218.7 277.5 -21.2% EBT 247.6 299.7 -17.4% Net Income 194.2 235.5 -17.6% EP
Slide 27: Thank You
THANK YOU For further Information: PT Prodia Widyahusada Tbk Prodia Tower. Jalan Kramat Raya No. 150 Jakarta 10430, Indonesia Email: investor.relation@prodia.co.id @prodia_lab @prodia_lab @prodia_lab 1500 830 Prodia.co.id